Tom Angell is the editor of Marijuana Moment. With over 25 years of experience in the cannabis reform movement, he focuses on the policy and politics surrounding cannabis and psychedelics, including regulation, business, and health implications. He has been featured in FILTER and Marijuana Moment.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Tom Angell's coverage largely focuses on cannabis legalization, laws, and industry. His articles predominantly feature government announcements and legal policy regulations related to cannabis. He also covers government and political aspects of the cannabis landscape.
Given this focus, individuals or organizations with expertise in governmental policies surrounding cannabis legalization, compliance with state laws, or insights into the intersection between politics and the cannabis industry may find success in reaching out to Tom Angell for potential coverage opportunities.
As his primary focus is on developments within the United States regarding cannabis legislation and regulation, pitches should be tailored to fit this geographic scope.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Tom Angell
The Massachusetts House of Representatives has voted to create a five-year pilot program allowing the use of psychedelics to treat mental health conditions.
By: Tom Angell
As Pennsylvania Democrats ramp up pressure to Republicans to allow a vote on marijuana legalization in the state Senate, a group of House members have filed a new bill that would prioritize issuing licenses to small, diverse and disadvantaged businesses through the state's existing medical cannabis program.
By: Tom Angell
The Food and Drug Administration (FDA) has issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations.
By: Tom Angell
The Food and Drug Administration (FDA) has issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September. “In recent years, interest in the therapeutic potential of psychedelic drugs has […]
By: Tom Angell
PA marijuana licensing bill; Congressional bill on cannabis/drug testing in hospitals advances; MA psychedelics vote; Hemp & marijuana op-ed
Two Trump administration cabinet members have announced that their departments are launching a new partnership to collaborate on research and
By: Tom Angell
Congressional researchers are detailing options for how lawmakers could respond to a recent Supreme Court decision to uphold the gun rights of people who use marijuana.
By: Tom Angell
Drinking a cup of tea infused with marijuana before going to bed can lead to a better night's sleep and an overall improved sense of happiness in life, according to a new study.
By: Tom Angell
Idaho voters will not get a chance to decide on an initiative to legalize medical marijuana on the November ballot, state officials have determined.
By: Tom Angell
About 97 percent of marijuana seized by California officials in unincorporated areas of the state came from counties that continue to ban licensed
